๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Unresectable Melanoma

Mirdametinib in Patients With Advanced NF1-mutant Melanoma NCT07237100Phase 21 site๐Ÿ“ San Francisco Kevin Kim, MD ยท Tests: Mirdametinib Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma NCT04598009Phase 22 sites๐Ÿ“ La Jolla๐Ÿ“ San Francisco University of California, San Francisco ยท Tests: Binimetinib, Imatinib Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial NCT07155317Phase 22 sites๐Ÿ“ Atlanta๐Ÿ“ Atlanta Emory University ยท Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ San Francisco Nurix Therapeutics, Inc. ยท Tests: NX-1607, Paclitaxel A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma NCT06624644Phase 2, Phase 39 sites๐Ÿ“ Newport Beach๐Ÿ“ San Francisco๐Ÿ“ Stanford Linnaeus Therapeutics, Inc. ยท Tests: LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide), Immunotherapy (Pembrolizumab), Immunotherapy (nivolโ€ฆ Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma NCT07631325Phase 1, Phase 21 site๐Ÿ“ Pittsburgh John Kirkwood ยท Tests: Axelopran, Nivolumab GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites๐Ÿ“ Goyang-si๐Ÿ“ Seoul๐Ÿ“ Seoul GeneMedicine Co., Ltd. ยท Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) Neoadjuvant Tebentafusp for Uveal Melanoma NCT06414590Phase 22 sites๐Ÿ“ Philadelphia๐Ÿ“ Philadelphia Thomas Jefferson University ยท Tests: Tebentafusp-Tebn AMT-253 in Patients With Advanced Solid Tumours NCT06209580Phase 1, Phase 21 site๐Ÿ“ Beijing Multitude Therapeutics Inc. ยท Tests: AMT-253 for injection Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626Phase 1, Phase 217 sites๐Ÿ“ Miami๐Ÿ“ Grand Rapids๐Ÿ“ Minneapolis Aulos Bioscience, Inc. ยท Tests: AU-007, Aldesleukin, Avelumab, Nivolumab ACTengineยฎ IMA203 Combined With mRNA-4203 NCT06946225Phase 14 sites๐Ÿ“ San Francisco๐Ÿ“ Boston๐Ÿ“ New York Immatics US, Inc. ยท Tests: IMA203, mRNA-4203 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site๐Ÿ“ Jacksonville Mayo Clinic ยท Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer NCT05896839Phase 1, Phase 226 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Kidney Biopsy Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment NCT04045691n/a59 sites๐Ÿ“ Graz๐Ÿ“ Innsbruck๐Ÿ“ Klagenfurt Pierre Fabre Pharma GmbH ยท Tests: Encorafenib, Binimetinib Duration of Anti-PD-1 Therapy in Metastatic Melanoma NCT02821013Phase 330 sites๐Ÿ“ Victoria๐Ÿ“ Coffs Harbour๐Ÿ“ Waratah Canadian Cancer Trials Group ยท Tests: Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma NCT05428007Phase 24 sites๐Ÿ“ Los Angeles๐Ÿ“ Boston๐Ÿ“ Boston NYU Langone Health ยท Tests: Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) NCT06246916Phase 3113 sites๐Ÿ“ Chandler๐Ÿ“ Gilbert๐Ÿ“ Tucson Regeneron Pharmaceuticals ยท Tests: fianlimab, cemiplimab, relatlimab+nivolumab Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma NCT07627698Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer NCT05361174Phase 1, Phase 211 sites๐Ÿ“ Los Angeles๐Ÿ“ Miami๐Ÿ“ Orlando Iovance Biotherapeutics, Inc. ยท Tests: IOV-4001 Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021 NCT07302607n/a1 site๐Ÿ“ Strasbourg University Hospital, Strasbourg, France MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma NCT05655312Phase 1, Phase 216 sites๐Ÿ“ Orange๐Ÿ“ Jacksonville๐Ÿ“ Miami Perspective Therapeutics ยท Tests: [203Pb]VMT01, [212Pb]VMT01, Nivolumab A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors NCT04913285Phase 148 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ San Diego Pierre Fabre Medicament ยท Tests: KIN-2787, KIN-2787 and binimetinib A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma NCT06594991Phase 212 sites๐Ÿ“ Los Angeles๐Ÿ“ Stanford๐Ÿ“ Hartford Memorial Sloan Kettering Cancer Center ยท Tests: Fianlimab, Cemiplimab, Ipilimumab Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary NCT02828202n/a27 sites๐Ÿ“ Amiens๐Ÿ“ Annecy๐Ÿ“ Besanรงon Assistance Publique - Hรดpitaux de Paris ยท Tests: Biological, Tissular, Quality of life Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients NCT06284590Phase 27 sites๐Ÿ“ Hartford๐Ÿ“ New York๐Ÿ“ Essen Philogen S.p.A. ยท Tests: L19IL2, L19TNF, L19IL2/L19TNF, KEYTRUDAยฎ A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel NCT06940739Phase 1, Phase 25 sites๐Ÿ“ Denver๐Ÿ“ Chapel Hill๐Ÿ“ Nashville Iovance Biotherapeutics, Inc. ยท Tests: IOV-3001 Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. NCT05727904Phase 382 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Los Angeles Iovance Biotherapeutics, Inc. ยท Tests: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites๐Ÿ“ Sacramento๐Ÿ“ Celebration๐Ÿ“ Miami Marengo Therapeutics, Inc. ยท Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivoยฎ in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma NCT07221734Phase 386 sites๐Ÿ“ Banja Luka๐Ÿ“ Sarajevo๐Ÿ“ Zenica mAbxience Research S.L. ยท Tests: MB11 (Proposed Nivolumab Biosimilar), EU-Opdivoยฎ, US- sourced Opdivoยฎ
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy